Application of Akt1 phosphorylated PMS2 protein as ovarian cancer treatment target

A therapeutic target, PMS2-T156A technology, applied in biochemical equipment and methods, microbial determination/inspection, material inspection products, etc., can solve problems such as MMR protein deletion

Inactive Publication Date: 2022-03-08
郑州大学第三附属医院
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

MMR protein deficiency leads to resistance to some chemotherapeutic drugs, such as methylation drugs, platinum compounds and fluoropyrimidine drugs, among which resistance to platinum compounds such as carboplatin and cisplatin for ovarian cancer and end...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Akt1 phosphorylated PMS2 protein as ovarian cancer treatment target
  • Application of Akt1 phosphorylated PMS2 protein as ovarian cancer treatment target
  • Application of Akt1 phosphorylated PMS2 protein as ovarian cancer treatment target

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0055] In order to make the object, technical solution and advantages of the present invention clearer, the present invention will be further described in detail below in conjunction with the examples. It should be understood that the specific embodiments described here are only used to explain the present invention, not to limit the present invention.

[0056] In view of the problems existing in the prior art, the present invention provides an application of Akt1 phosphorylated PMS2 protein as a therapeutic target for ovarian cancer. The present invention will be described in detail below in conjunction with the accompanying drawings.

[0057] Such as figure 1 As shown, the method for identifying Akt1 phosphorylated PMS2 protein as ovarian cancer treatment target provided by the embodiments of the present invention comprises the following steps:

[0058] S101, the relationship between activated Akt1 and p-PMS2 was detected by Western Blot;

[0059] S102, detecting the chang...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of biology, and discloses an application of an Akt1 phosphorylated PMS2 protein as an ovarian cancer treatment target, and a method for identifying the Akt1 phosphorylated PMS2 protein as the ovarian cancer treatment target comprises the following steps: detecting the relationship between activated Akt1 and p-PMS2 through Western Blot; detecting the change of the migration ability of the ovarian cancer cells after the down regulation of the p-PMS2 T156; detecting the change of the invasion ability of the ovarian cancer cells after the down regulation of the p-PMS2 T156; detecting the change of the clone formation ability of the ovarian cancer cells transfected with the PS2-T156A by a plate cloning method; and the influence of apoptosis of the transfected PMS < 2 >-T156A ovarian cancer cells is detected through a flow cytometry and Western Blot. The invention confirms that threonine at the site 156 of the PMS2 is phosphorylated by Akt1 for the first time, and provides a new direction and target for research and treatment of ovarian cancer.

Description

technical field [0001] The invention belongs to the field of biotechnology, and in particular relates to an application of Akt1 phosphorylated PMS2 protein as a therapeutic target for ovarian cancer. Background technique [0002] Currently, ovarian cancer is the most lethal gynecological malignancy, of which epithelial ovarian cancer accounts for about 85-90%. Because of its inconspicuous early clinical symptoms and the lack of early diagnosis methods, most of them are diagnosed at an advanced stage. According to reports, in 2014, there were 21,980 new cases of ovarian cancer in the United States, and 14,270 deaths. About 2 / 3 of the new cases were found to be FIGOIII-IV, that is, they had metastasized outside the pelvis. The current gold standard for clinical treatment of ovarian cancer is cytoreductive surgery combined with platinum-based chemotherapy. Although most patients respond well to chemotherapy at the initial treatment, some patients still relapse in a short perio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12Q1/6886C12Q1/02G01N33/574G01N33/68
CPCC12Q1/6886G01N33/57449G01N33/68G01N33/5005C12Q2600/158
Inventor 高芳芳
Owner 郑州大学第三附属医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap